then Today, and Zach with progress look We’ll patient forward answering and we questions. afternoon, in third recent exciting and everyone, and events. we to begin financial will metrics, Thank our quarter to key our welcome QX Good clinical results, our pipelines. you, call. results our your cover innovation Cassie. then share discuss will
referring I’ll on not you’re webcast, Relations site. the the our on from Investor to be slides If presentation
X. Slide to Turning
XX them thousands treat/improve consistent Clinical About remarkable. MRIdian now to outcomes have MRIdian, XX are reported others curiosity systems installed clinically can’t. patients what over have our of in backlog. with We compelling. and on on system is XX,XXX mission Our and that is treated been
of Our clinical to improve customers care. to vital growing efforts our the body have over and is change paradigm trials. data This XX of initiated
with begin Slide Let’s X. results our QX on
We XXXX. have continue to performance solid financial in
This quarter, XXXX. orders QX X we another delivered X MRIdian in versus
have first the orders X of We XX received in than months in XXXX months all XXXX. more
X $XX for now increase quarter, grew was or points million year. backlog the $XXX year was basis at million. based Our primarily prior revenue stands on Revenue for Total X,XXX over XX%, units. over gross prior and $XX of million an margin quarter XX% the
was flat. All keeping of while this achieved operating growth roughly expenses
perspective, million on cash and in cash we approximately the used with of a from quarter $XX Finally, $XXX ended million hand.
our execution results, financial on we Beyond solid commercial and clinical, innovation pipelines. continue
Turning anchor desires. critical X to X. Slide It’s customer on important to always
clinical and low these meets MRIdian work critical Customer elements toxicity. or to has to continues criteria. twofold. the These input the of that meaningful in no five First, deliver the customers want fractions, clinical margins, dose no meaningful want or an define Number clear they fewer how ablative with second, implants, which higher shaped represent grade-X body and They success. only they MRIdian drive our And, goals, very is are are clinical data. X to about tight X. our thing pipeline
cancer patient programs to SMART, frontline more become and to of The the our therapy customers’ greatly adoption, of cycle to proof, leading utilization and First care. is benefiting second, therapy. expand MRIdian clinical more
ubiquitous to in and we X. on treat Slide Last to Turning more insights cancers. a webinar who value both X with conducted key week, provided leaders, opinion tough MRIdian’s
cancer. presented yet XXX cancers survival, versus while patients grade-X technology. Dr. XX on months data in pancreatic what’s month seen minimizing survival maximize or in is delivered XX% to with was MRIdian survival prospective to Michael and local across survival Two-year MRIdian survival, MRIdian compelling goal about of minimal compares effects. on with XX patients, higher XX is toxicity. These which sites, treated commonly to for levels study. commonly are Our side therapy. favorably consistent were which control conventional excellent and been a XX% Chuong control was multicenter with tough-to-treat data-set in Median with local demonstrated customer conventional another
cancer prove results he ubiquitous next that critical value of more the the anticipate. highlighted of Nagar to Nagar designed we we strive value. Dr. like life highlighted of On prostate to series quality and data prove a Dr. upcoming delivers slide, incredible trials In are MRIdian. cancers the in eagerly prostate, groundbreaking the
is trial a trial, as and prove if XX% MIRAGE MIRAGE successful, patients. reduction and toxicity in or conventional delivers control radiation MRIdian Phase greater to designed therapy. a a the First, ViewRay to compared that III is for prostate landmark event grade-X randomized represents
safely designed to can delivered is technology, post-prostatectomy the weeks conventional prove X-fraction X on that trial be treatment MRIdian SCIMITAR needle-moving trial. of the Second, to X SBRT another versus
be economic increase therapy alternative with the has MRIdian. to randomized conventional demonstrate is SBRT noninvasive, to Cornell of trials profile just for catheter Dr. opportunity versus the these effective Nagar and their directly a as stressed fractions. And XX X MRIdian X-fold a of prove translating in inception safe prostate designed clinical surgery. first volumes second, the since as effect that we that the can this X. SHORTER, take viable, for safety to fractions holds outstanding aggregate designed is to a FORT down that therapy and trial and prove value and Finally, of trial are II to FORT no controlled X-fraction strategic value Phase to The to is X-fraction the therapy promise
the trials. They our According nothing commercial cutting-edge ASTRO to customers. half our there’s the XX at the to cancers, it with week. tough-to-treat Slide afforded Slide releases X. doing. of depth Phase dozen industry. randomized III Turning are opportunity and the data highlight recent everything clinical therapy important filing. was underway. was The customer innovations. in Phase recent the clinical treat data to palpable be The toughest X last with in response key back us value was activity leaders, highlight imminent launch ubiquitous wait our things single-fraction great experimenting ASTRO They’re and to for and we else highlights from studies studying front, It presence the cancers excitement cannot over to and opinion to XXX(k) the I clinical are To a in alike. demonstrating like of terrific. like of newest controlled breadth and dozens cancer to feasibility types. work They summarize customers have on trials it’s They’re and
XX. of Speaking to moving Slide which,
FDA On include as the on tissue are MRI tracking on accepted real-time with clinicians and includes for elements parallel newest the imaging MRIdian The utility. innovation features, for submission steps, features focused customers. tools, a new sequences, by multi-planar These workflow. items the automated and feedback for review integration highest and the work new on-table the recently front, prospective beam and also on-table our of ability customers to display. the generation throughout the such brain automated our auto-contouring enhancing priority patient gating, in clinical adaptive workflow treatment Advancements workflow of XXX(k) was expanding efficiency package
sign move for an will clinical customers exactly to important incremental Turning efforts. commercial customers. underway. to needle proof it and to to capital This more over that process pipelines in that clinical share of changing the and With the financial actively turn paradigm really I customer’s innovations now We more XX. what our MRIdian to Momentum purchasing care identify desire. to has understanding, our systems, work clear Zach and improving to on and the led that Slide our innovation accrue results. is we our hard energy allocate and deliver
